Latest News and Press Releases

HUDDINGE, Sweden, Nov. 13, 2003 (PRIMEZONE) -- Karo Bio today announced that the company immediately will obtain rights to technologies, lead compounds and preclinical data from its joint diabetes...

HUDDINGE, Sweden, Oct. 15, 2003 (PRIMEZONE) -- Karo Bio (Other OTC:KARBF): -- Merck & Co., Inc. has decided to discontinue the development of one compound in the collaboration. A second...

HUDDINGE, Sweden, August 21, 2003 (PRIMEZONE) -- Scientists from Karo Bio (Other OTC:KARBF), together with scientific collaborators, have for the first time shown results that may offer a new...

HUDDINGE, Sweden, August 19, 2003 (PRIMEZONE) -- Karo Bio (Other OTC:KARBF) announces today that Merck & Co, Inc. (NYSE:MRK) has decided to discontinue development of the first of the two...

HUDDINGE, Sweden, July 15, 2003 (PRIMEZONE) -- Karo Bio Quarterly Report April - June 2003 - A second preclinical milestone reached and milestone payment received in the Merck collaboration. -...

HUDDINGE, Sweden, June 5, 2003 (PRIMEZONE) -- Karo Bio (Other OTC:KARBF), one of the leading biotechnology companies in Europe, will be attending the BIO 2003 Convention, the largest annual biotech...

HUDDINGE, Sweden, May 8, 2003 (PRIMEZONE) -- Karo Bio (Other OTC:KARBF): A significant preclinical milestone has been achieved in the estrogen receptor collaboration between Merck & Co., Inc...

HUDDINGE, Sweden, April 23, 2003 (PRIMEZONE) -- Karo Bio (Other OTC:KARBF): -- A novel first-in-class compound for type 2 diabetes has been identified in the collaboration with Abbott...

HUDDINGE, Sweden, April 10, 2003 (PRIMEZONE) -- At Karo Bio AB's (Other OTC:KARBF) Annual General Meeting on Wednesday April 9, 2003 the following was resolved. Dividend No dividend is to be paid...

HUDDINGE, Sweden, March 27, 2003 (PRIMEZONE) -- Abbott Laboratories and Karo Bio AB (Other OTC:KARBF) today announced that they have identified a novel, first-in-class compound, A-348441, for the...